Business News • PR NewsWire • First patient treated in Turnstone's lung cancer trial combining novel viral cancer therapy with approved checkpoint inhibitor

First patient treated in Turnstone's lung cancer trial combining novel viral cancer therapy with approved checkpoint inhibitor

First patient treated in Turnstone's lung cancer trial combining novel viral cancer therapy with approved checkpoint inhibitor

Combination of Turnstone's oncolytic viral immunotherapy with checkpoint inhibitors showed promising results in preclinical testing OTTAWA, April 26, 2017 /PRNewswire/ - Turnstone Biologics Inc. announced today that treatment has been initiated on the first patient in the company's...

View More : http://www.prnewswire.com/news-releases/first-patient-treated-in-turnstones-lung-cancer-trial-combining-novel-viral-canc...

Releted News by prnewswire

Future Looks 'Spectacular' for Champagne and Sparkling Wine - According to New Research From just-drinks and The IWSR

The Capitol Hotel Tokyu Announces Appointment of New General Manager